Immunic Secures European Patent for Vidofludimus, Strengthening Market Position in Biotechnology

Immunic Secures Key European Patent for Vidofludimus Calcium

Immunic, Inc., a late-stage biotechnology company specializing in novel oral therapies for neurological and gastrointestinal disorders, achieves a significant milestone with the granting of European patent EP3713554 by the European Patent Office (EPO). This patent protects the label-relevant dosing regimens for Immunic's lead candidate, vidofludimus calcium (IMU-838), which shows promise across several indications, notably in treating multiple sclerosis. The granting of this patent secures Immunic’s intellectual property rights in Europe until at least 2038, with possibilities to extend protection through a Supplementary Protection Certificate (SPC) into 2043, should they seek this additional safeguard.

This intellectual property advancement marks a critical component of Immunic's long-term strategy to solidify its market position in the increasingly competitive field of biotechnology. According to Immunic's CEO, Daniel Vitt, the patent forms a vital part of the company's comprehensive approach to safeguarding its innovations. The patent covers not only the drug itself but also various formulations, including its salts, solvates, and free acid forms. Furthermore, Immunic has already obtained a U.S. patent from the USPTO earlier this year, enhancing the protection framework for vidofludimus. This dual-layered intellectual property strategy is aimed at ensuring multiple degrees of market exclusivity in response to regulatory approvals, thereby providing a competitive edge that extends at least until 2041 in the United States and 2039 in Europe.

Immunic's extensive patent portfolio also includes various protections for the composition of matter related to vidofludimus, treatment protocols for both relapsing and progressive multiple sclerosis, specific dosing strategies, and advanced production methods. By reinforcing their intellectual property framework, Immunic not only aims to protect the potential of vidofludimus but also seeks to foster ongoing innovations that could significantly improve the quality of life for patients grappling with debilitating conditions.

In addition to the patent news, Immunic remains focused on advancing its ongoing clinical trials to assess the efficacy and safety of vidofludimus. The company’s commitment to developing innovative therapies continues to be underscored by a steadfast dedication to research and patient outcomes. The successful implementation of their intellectual property strategy may attract further investments and partnerships as Immunic moves closer to delivering life-changing treatments.

Immunic's recent patent win exemplifies not just a guarding of its innovations but a strategic positioning for future growth in a rapidly evolving industry devoted to addressing challenging medical conditions.